RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. [electronic resource]
Producer: 20141021Description: 345-54 p. digitalISSN:- 1556-1380
- Animals
- Anticoagulants -- pharmacology
- Bone Neoplasms -- metabolism
- Carcinoma, Non-Small-Cell Lung -- metabolism
- Enoxaparin -- pharmacology
- Female
- Humans
- Lung Neoplasms -- metabolism
- Mice
- Mice, Nude
- Osteolysis -- drug therapy
- Osteoprotegerin -- immunology
- RANK Ligand -- antagonists & inhibitors
- Survival Rate
- Tumor Burden
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.